Compare STTK & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STTK | CHMG |
|---|---|---|
| Founded | 2016 | 1833 |
| Country | United States | United States |
| Employees | N/A | 343 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 257.8M |
| IPO Year | 2020 | 1995 |
| Metric | STTK | CHMG |
|---|---|---|
| Price | $5.99 | $53.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | $7.00 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 574.2K | 3.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.57% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ 1.53 |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $37.32 |
| Revenue Next Year | N/A | $9.13 |
| P/E Ratio | ★ N/A | $35.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $40.71 |
| 52 Week High | $6.13 | $65.50 |
| Indicator | STTK | CHMG |
|---|---|---|
| Relative Strength Index (RSI) | 72.78 | 34.49 |
| Support Level | $1.85 | $52.75 |
| Resistance Level | N/A | $53.51 |
| Average True Range (ATR) | 0.40 | 1.40 |
| MACD | 0.17 | -0.44 |
| Stochastic Oscillator | 89.34 | 5.38 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.